



The Fibrous Dysplasia and McCune-Albright Syndrome Association (FD/MAS) respectfully requests your support as a Sponsor, to support the **International FD/MAS Consortium Biennial Congress**, to be held in Madrid, October 24-26, 2025.

This sponsorship will directly contribute to the organization of the congress together with the **fourth in-person meeting of the International FD/MAS Consortium (ICFDMAS)** and the Emerging Researchers Poster Exhibition.

Additionally, your sponsorship will fund travel and accommodation expenses for researchers, patients, and families with limited resources, thus ensuring diverse, inclusive, and enriching participation.

THE NEED

Fibrous Dysplasia/McCune-Albright Syndrome (FD/MAS) is a rare disease that affects between 1 in 100,000 and 1 in 1 million people. Its origin is a mutation in the GNAS gene,



and its clinical expression is extremely variable. The characteristic bone lesions can cause deformities, fractures, and, when they affect the skull, compromise senses such as vision, hearing, or smell.

In the most severe cases, FD/MAS is associated with complex endocrine disorders and multisystem manifestations. Its symptoms are often debilitating and appear at an early age, lasting a lifetime.

The development of effective treatments requires ongoing and collaborative research worldwide. Therefore, this Congress is an essential platform that brings together international experts, patients, families, and emerging researchers, fostering an open and multidisciplinary dialogue that can mark a turning point in the approach to this disease.



CONGRESS OBJECTIVES

1. Strengthen the FD/MAS community

Promote support networks among patients, caregivers, physicians, and researchers. It will include educational sessions, personalized medical advice, a video history project, and spaces for meeting and exchange.

2. Disseminate the Latest Scientific Advances

World leaders in FD/MAS have been invited to share clinical and laboratory research results.

3. Foster Scientific Collaborations

Dedicated spaces and times will be offered for researchers to connect, develop synergies, and propose new lines of research.

4. Update Treatment Guidelines

One of the major achievements expected is the dissemination of the recently updated clinical guidelines published in 2019, under the coordination of the International Consortium. The FD/MAS Association will play a key role in their dissemination and implementation.

5. Promote Emerging Researchers

They will be given visibility through presentations and posters, thus supporting the future of research in DF/MAS.



IMPACT

In the short term, this conference seeks to empower the FD/MAS community, reduce the isolation associated with rare diseases, and promote the inclusion of underrepresented groups.

In the long term, the event will be a fundamental pillar for advancing research, improving available treatments, and strengthening an international network of support and shared knowledge. It will also ensure that new evidence-based treatment guidelines are clearly and accessible to all stakeholders.

For more information:

CONTACT:

info@displasiafibrosa.es

00 34 679 36 76 86